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and overcome the effects of under-valuation of vaccina-
tion on a global scale.
METHODS: Estimates of vaccine-preventable cases
worldwide, vaccine coverage levels, disease incidence,
vaccine costs and cost-effectiveness were obtained
through in a four-stage process. First, an electronic 
document search was conducted. Second, government
documents and academic publications were reviewed.
Third, academic and government experts in vaccine cost-
effectiveness were contacted to obtain several estimates.
Fourth, the epidemiological and economic data obtained
from the ﬁrst two stages were converted to the following
common units: US$, LYS, deaths, QALYs, and DALYs, 
to allow for further economic analyses of the value of 
vaccination.
RESULTS: Disease: Direct or indirect savings Smallpox
$300 million in direct costs per year; Polio US$13.6B in
total savings worldwide; Measles US$10 per DALY
Cholera $770 million; Malaria $100B GDP lost per year
in Africa; MMR $100 million direct medical costs; DTPa
$23.6B direct and indirect costs; Hib $5B direct, $12B
indirect costs in US.
CONCLUSIONS: Vaccines are unquestionably one of 
the most cost-effective public health measures available,
yet they are undervalued and underutilized throughout
the world. It is important for international agencies, gov-
ernments, and health policy makers to keep this preven-
tive measure in the spotlight. It is important to remind
parents, the general population, and health care providers
worldwide to take advantage of this life-saving measure
so that no one will suffer diseases that can so easily be
prevented.
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OBJECTIVE: The objective of this study is to describe
the demographic proﬁles, drug costs, medication utiliza-
tion, and chronic disease characteristics of the insured
elderly population in the United States, with particular
emphasis on those with high outpatient drug expenses.
METHODS: Prescription claims data from the Merck-
Medco National Probability Sample Database, a 10%
stratiﬁed random sample of continuously eligible lives
covered by Merck-Medco during 2000, was used for the
analysis.
RESULTS: 495,260 insured elderly (age > = 65) were
identiﬁed in the sample database. Demographically,
49.7% were female, the mean age was 75.8 years (sd 7.5)
and they were predominantly from Middle Atlantic
(23.5%) and South Atlantic (23.3%) regions of the
country. Seventy-seven percent ﬁlled one or more pre-
scriptions (range 1–480 prescriptions per person per year)
and this number varied signiﬁcantly by age and region.
Fifty-ﬁve percent of elderly patients ﬁlled prescriptions for
conditions related to the cardiovascular system, 22.0%
for the endocrine, 19.4% for the GI, 19.0% for the CNS
and 9.0% for the respiratory system. In terms of expen-
diture (expressed in Average Wholesale Price), 32.5% of
the total expenditure was for cardiovascular medications,
10.4% for GI, 5.6% for endocrine and 3.5% for respi-
ratory medications. Overall, 10.4% of the elderly had a
medication expenditure of $4,000 or more, 38.8% had
expenditures between $1,000 and $4,000, 27.7% had
cost that averaged $443 and the remaining 23.0% 
had no drug expenditure during 2000. Regression model
analyses revealed that increasing age (p-value = 0.04),
female gender (p-value < 0.01), and residence in Middle
Atlantic, New England or Paciﬁc regions (p-value < 0.01)
were signiﬁcant and independent risk factors for increas-
ing medication costs.
CONCLUSIONS: There are demographic and chronic
conditions associated with higher medication utilization
that are important to consider when developing a policy
for national prescription drug coverage for the elderly.
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Prescription drug coverage issues have generated consid-
erable attention within health care and political agendas.
To allocate scarce resources efﬁciently, it is important to
identify the characteristics of individuals with the highest
level of out-of-pocket expenditures for prescription 
medications.
OBJECTIVE: To identify factors explaining the variance
associated with individual out-of-pocket prescription
drug costs.
METHODS: We analyzed data from the household com-
ponent and event ﬁles of the 1996 Medical Expenditure
Panel Survey (MEPS), with brand-generic status informa-
tion obtained from MULTUM®. Of the 22,601 individ-
uals, 14,015 (62%) incurred prescription expenditures.
Out-of-pocket prescription costs were regressed on demo-
graphic factors, socioeconomic factors, perceived health
status, type of health insurance coverage, perceived access
to care, prescription drug characteristics, and health 
care cost data. Person level weights were included in the
regression model. Variance estimation was performed to
adjust for the complex survey design employed by MEPS.
RESULTS: The mean out-of-pocket prescription drug
cost was $166 (se = 4.61). Minorities had lower out-of-
pocket costs ($117, se = 7.87) compared to Caucasians
($175, se = 5.05), whereas uninsured consumers had
greater out-of-pocket costs ($181, se = 20.29) compared
to consumers with private insurance ($156, se = 4.76).
Signiﬁcant (alpha = 0.05) predictors with positive coefﬁ-
